Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the otw_tsw domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/wp-includes/functions.php on line 6114
CEO Blog: February 2018 – U.S. Stem Cell, Inc

CEO Blog: February 2018

Dear Shareholders and Friends,

Thank you all so much for taking the time to learn more about our recent progress.  In this post, we want to take a moment to share key highlights from 2017, as well as update you with new developments for 2018.

A strengthening economy, an increase in marketplace demand as more people learn about stem cell treatments and alternatives to opioids, and an increase in more doctors and physicians advancing their skill sets to include stem cell treatments are all reasons why we are beginning to see steady growth.  

We are pleased to announce that our proprietary AdipocellTM stem cell kit has reached 10,000 units in sales — an indication that the marketplace is starting to demand stem cell therapy more readily.  Although we reached the goal in January of 2018, much of the effort behind attaining that benchmark was done in 2017, and our hard work is paying off.

We are also proud to announce we have completed more than 10,000 stem cell procedures since 1999 for a variety of indications — including orthopedic, autoimmune, degenerative and neurological diseases.  We are pleased to share that, to-date, we have trained more than 700 physicians worldwide on stem cell therapy, and we anticipate that number will only continue to increase.

The FDA’s issuance of guidance documents in November of last year also has also signaled to the marketplace the legitimacy of stem cell therapy as a practice.  Because our science is based on the use of a patient’s own (autologous) stem cells, we are confident that the issuance of these guidance documents moves us closer to a time when there will be clear differentiation between treatments that are autologous, versus those that involve the use of donated, off-the-shelf, third-party stem cells that may or may not have been genetically manipulated and clearly require more regulation.   

USRM is working with one of the best legal teams based in Washington, D.C., to help communicate with the FDA while preserving the rights of patients to harness their bodies’ own healing potential.  We have joined forces with the Academy of Regenerative Practices to ensure that our physicians have a right to practice regenerative medicine with their consenting patients.  We are proud sponsors of the upcoming ARP annual conference March 1st – 3rd where our Chief Science Officer Dr. Kristin Comella will be a keynote speaker.

Demand for stem cell therapy is anticipated to be at an all-time high this year, as more patients seek the growing trend of using their own cells to heal various injuries and diseases.  As a result, we have expanded our clinic locations to include West Palm Beach. This expansion is timely, given the emerging and explosive demand now coming from patients and the marketplace.   We have worked very hard as a team to temper our growth in order to be ready to meet the demands of a growing market at just the right time.  We are confident that timing is now.

USRM technologies are now offered in six continents with interest from various countries throughout the world growing.  We have experienced a few delays with our facilities opening in Kuwait due to unforeseen regulatory hurdles.  These types of challenges are very familiar to us, we know it is part of the landscape and we know how to address them.  We will continue to work with our legal team to neutralize these concerns and move forward with bringing stem cell treatments to the patients in the Middle East.

The recent opioid crisis in America means more patients are seeking alternative therapies to pharmaceuticals and surgery for coping with and managing chronic pain.  Stem cell therapy may offer new solutions for these patients experiencing systemic diseases, orthopedic conditions, neurological symptoms and other therapies for an aging population.  Shape Magazine discusses this subject in their most recent issue, where they mention Dr. Kristin Comella and her work with autologous stem cells.  Shape Magazine is the first of many highly-visible mentions where Dr. Comella has been featured, including “The Healing Miracle: The Truth About Stem Cells,” a docuseries that interviews renowned experts in the field of stem cell medicine and explores in-depth the benefits and application of regenerative stem cell therapy.  Dr. Comella is featured in Episode five of the docuseries; that interview can be viewed in its entirety here.  

Due to the overwhelming response we have had as a result of that docuseries, we were inspired to launch our own live webinar series in order to educate and inform our audience, as well as provide a forum for Q & A on an anonymous platform.   Facts About Stem Cell Therapy,” which had its first live broadcast February 9th, was very well received and had more than 100 participants.  Dr. Comella answered questions live for nearly two hours, which is another demonstration of the growing demand for information about this emerging, holistic, regenerative therapy. If you are interested in joining our mailing list to receive notification for our next stem cell webinar, click here.

In honor of Valentine’s Day and the month of love, our second webinar was broadcast live February 17th and featured Dr. Comella and fitness expert and world renown leading biohacker Ben Greenfield.  The webinar, which is entitled Enhancing Sexual Performance with Stem Cell Therapy,” provides the opportunity to learn more about stem cell therapy and enhancing sexual performance.  Greenfield, who recently underwent penile enhancement with stem cell therapy, documented his journey in the January issue of Men’s Health magazine.  He was successful at increasing both size and rate of performance.  To listen to that webinar in its entirety click here.

Our commitment to this emerging science is unwavering and we will continue to expand efforts to help patients maximize their health with this amazing technology.  We thank you for your interest and continued support and welcome the chance for an ongoing dialogue to answer any questions you may have.

Warmest regards,

Mike Tomas,

President and CEO